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Table 1
Comparison of MNC collections on Cobe Spectra and Spectra Optia.
Autologous Allogeneic
Cobe Spectra (n¼71) Spectra Optia (n¼26) p Cobe Spectra (n¼21) Spectra Optia (n¼8) p
Patient weight (kg) 89.2 [76.2;99.8]1 86.1 [63.4;112.8] 0.882 82.9 [67.1;89.7] 81.4 [76.1;115.8] 0.55
Pre WBC (x106/mL) 48.5 [33.0;70.3] 60.2 [51.6;71.1] 0.16 61.2 [51.2;69.1] 43.9 [43.1;52.3] 0.030
Pre CD34 (cells/ul) 75.0 [42.0;140.0] 104.0 [42.0;147.0] 0.28 114.0 [69.0;147.0] 65.5 [40.0;217.5] 0.42
W B processed (L) 27.4 [23.5;30.8] 16.8 [14.6;18.7] <0.001 22.0 [19.3;27.2] 16.3 [15.2;18.2] <0.001
Product Hct (%) 2.1 [1.7;3.4] 1.3 [1.0;2.1] <0.001 2.4 [1.9;3.1] 1.2 [1.1;1.5] <0.001
CD34+ (x106/kg) 6.2 [3.2;11.2] 10.2 [4.4;15.4] 0.059 8.1 [6.2;9.7] 6.8 [3.7;12.0] 0.92
CD34 CE2 (%) 31.2 [21.5;38.5] 50.1 [42.3;54.7] <0.001 24.4 [19.6;29.3] 44.3 [37.8;50.6] <0.001
MNC CE2 (%) 34.3 [25.2;49.2] 73.7 [50.6;81.2] <0.001 33.2 [27.0;47.2] 65.1 [61.5;82.6] <0.001
1 Results are depicted as median [IQR].
2 p values were calculated with Mann-Whitney U test.
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processed blood while acquiring the targeted CD34+ cell
dose. Retrospective analysis of mononuclear cell (MNC) col-
lections was performed in 61 auto-HCT candidates and 28
donors for allo-HCT using Cobe Spectra or Spectra Optia. The
target CD34+ cell dose was 10x106/kg for multiple myeloma
and 5-7x106/kg for lymphomas. For healthy allo-HCT donors
the target depended on the recipient diagnosis. Collection
efﬁciency was evaluated as [total number CD34+ cells in
product/(peripheral blood CD34+ cell count x blood volume
processed)]. Pre-apheresis WBC and CD34+ measurements
were not signiﬁcantly different. The implementation of
Spectra Optia in auto-HCT recipients increased the CD34+
CE2 from 31.2% to 50.1% compared to Cobe Spectra, and from
24.4% to 41.3% in allo-HCT donors. This translated in signiﬁ-
cantly lower volumes of blood processed to obtain an equal
CD34+ dose (Table I). In addition, MNC CE2 signiﬁcantly
increased and median Hct in the product decreased on
Spectra Optia, indicating a higher purity of the collected
product. Moreover, we witnessed an increase of the CD34+
collection efﬁciency on Spectra Optia in years 2014 versus
2013, indicating a learning curve was inherent to the
implementation. Our study shows that the integration of
MNC collections on Spectra Optia greatly increased efﬁciency
of CD34+ cell collection in comparison to the Cobe Spectra.
Consequently, lower blood volumes were processed to
obtain equal to better CD34+ cell dose. These results invite to
assess further the impact of implementation of Spectra Optia
on the number of collection days.173
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nocompetent host express the type II latency antigens LMP1
and LMP2 which can serve as potential targets for immu-
notherapy. For many patients with chronic active EBV
(CAEBV) and/or relapsed EBV+ Non Hodgkin Lymphoma
(NHL) or Hodgkin Lymphoma (HL) the only potential cura-
tive option is allogeneic hematopoietic stem cell transplant
(allo-HSCT). However, relapse rates remain high (>50%) and
the risk of inducing graft versus host disease (GvHD) after
DLI limits the broad application of this approach. We hy-
pothesized that the administration of donor-derived cyto-
toxic T lymphocytes (CTLs) directed to LMP1/2 (LMP-CTL)
would rapidly restore LMP-speciﬁc T-cell immunity and
prevent relapse in these high-risk patients without
increasing the incidence of GvHD. LMP-CTLs were expanded
using donor monocytes and EBV transformed lympho-
blastoid cell lines, transduced with an adenoviral vector
encoding either LMP2 (n¼4) or DLMP1 and LMP2 (n¼11).
Characterization of CTL lines at cryopreservation revealed
CD4+ and CD8+ cells which were predominantly effector
and effector memory phenotype. CTL lines had LMP2
(+/-LMP1) speciﬁc activity as determined by ELISPOT and
cytotoxicity assays. Fifteen patients (n¼5 HL, n¼4 B-cell
CAEBV/NHL, n¼6 T-cell CAEBV/NHL) received 2 infusions of
CTLs (dose range: 0.4-3x10e8/m2) approximately 100 days
post HSCT. No immediate toxicities related to CTL infusions
were observed. Infusion of LMP-CTLs resulted in a
maximum 2.5 fold increase in the frequency of LMPs pre-
cursors as detected by IFNg eliSPOT assay. No patient
developed de novo GVHD post CTLs. GVHD was seen in 4
patients with a pre-existing history (1 patient with DLBCL
experienced grade II skin GvHD controlled with steroids, 2
patients (1 NK-T and 1 HL) showed signs of grade I GvHD
promptly controlled with steroids. One patient with DLBCL
developed grade III GvHD after weaning immune suppres-
sion and subsequently developed sepsis and died 10 months
after an HLA matched-unrelated HSCT). 13 patients were in
remission at the time of CTL infusion and 12/13 of these
patients remained in remission for a median of 30 months
post CTLs (range 6-90 months). One patient with NK/T cell
NHL relapsed 6 months post CTLs and died of progressive
disease. Two patients (1HL and 1 T-cell CAEBV) received
CTLs for relapsed disease after HSCT and both died of dis-
ease. Disease progression in the patient with HL, was likely
due to immune-escape since tumor biopsies obtained post
CTL were EBV-negative. In conclusion, donor-derived LMP-
CTLs seem to be well tolerated in high-risk patients with
CAEBV and/or EBV+ lymphoma post HSCT. Furthermore, the
use of donor-derived tumor-directed T-cells as adjuvant
therapy post HSCT may restore LMP-speciﬁc T-cell immu-
nity and prevent relapse in this high-risk patient pop-
ulation.
